Chronic Lymphocytic Leukemia (CLL)

CLL is a cancer of mature B-lymphocytes that accumulate in the blood, bone marrow, and lymph nodes. It is the most common leukaemia in adults in Western countries, typically diagnosed in older adults often incidentally on a blood test. CLL ranges from an indolent condition managed with monitoring alone for many years, to a progressive disease requiring targeted therapy. It is closely related to small lymphocytic lymphoma (SLL), which is the same disease presenting primarily as lymphoma.

Watch and wait means that a patient has been diagnosed with CLL but does not yet meet criteria for starting treatment. Many patients with early-stage CLL can be safely monitored with regular blood tests and clinical assessments without requiring immediate therapy — and early treatment in asymptomatic early-stage CLL does not improve outcomes. Treatment is initiated when specific criteria are met, such as progressive lymphocytosis, symptomatic anaemia or thrombocytopenia, significant lymph node enlargement, or disease-related symptoms.

del(17p) refers to a deletion of chromosome 17p, which removes the TP53 tumour suppressor gene. Patients with del(17p) CLL (or TP53 mutation by sequencing) have disease that does not respond to standard chemotherapy agents (fludarabine, chlorambucil). This means that if these patients receive conventional chemoimmunotherapy, they will not achieve meaningful or lasting remission. All CLL patients must be tested for del(17p)/TP53 before starting treatment, and those who test positive require a BTK inhibitor or venetoclax-based regimen.

BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) block a signalling enzyme essential for CLL B-cell survival. They are taken as daily oral tablets continuously until disease progression or intolerance. Venetoclax targets BCL2, a protein that prevents CLL cells from undergoing normal cell death. When combined with obinutuzumab (anti-CD20), venetoclax is given for a fixed 12-month duration, which appeals to patients preferring a time-limited treatment. Both approaches are effective first-line options; the choice depends on patient factors, comorbidities, and preference.

Richter transformation is the development of an aggressive lymphoma (most often diffuse large B-cell lymphoma) from CLL. It occurs in approximately 5% of CLL patients over their lifetime and presents with rapid lymph node enlargement, new B symptoms (fever, night sweats, weight loss), and a sharply rising LDH. It requires biopsy confirmation and is treated as an aggressive lymphoma rather than CLL, with outcomes considerably poorer than standard CLL. CAR-T therapy is increasingly used for Richter transformation at specialist centres.

Resistance to covalent BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) commonly develops through acquisition of the BTK C481S mutation. At progression, testing for BTK resistance mutations is important. Options include switching to venetoclax-based therapy (cross-class switch strategy) or, for patients who have progressed on both BTK inhibitors and venetoclax, pirtobrutinib — a non-covalent BTK inhibitor approved for this scenario. Clinical trials for BTK PROTAC degraders and other novel agents are available at specialist centres.

CLL primarily affects older adults (median age ~70), but a small proportion of patients are diagnosed under 50 years of age. Younger patients face a lifetime of disease management with likely multiple treatment lines over decades. For younger patients, treatment sequencing strategy — including the question of allogeneic stem cell transplantation candidacy and fertility preservation — should be discussed with a specialist CLL haematologist at a dedicated centre.

Yes — CLL is an active area of clinical research with numerous trials investigating next-generation BTK inhibitors (pirtobrutinib, BTK degraders), novel venetoclax combinations, MRD-guided treatment strategies, bispecific antibodies, and CAR-T therapy. Patients with del(17p)/TP53-mutated disease, those progressing after BTK inhibitors and venetoclax, and those with Richter transformation are particularly strong candidates for trial enrolment.

Yes. CancerFax supports CLL patients by reviewing blood and molecular test results (FISH cytogenetics, IGHV status, TP53 mutation sequencing), coordinating specialist haematology second opinions, and identifying access pathways to BTK inhibitors, venetoclax regimens, and clinical trials for del(17p)/TP53-mutated and double-refractory CLL.

For patients with Richter transformation, CancerFax can help identify CAR-T-accredited centres and bispecific antibody trials. For patients in regions where novel agents are not accessible, CancerFax coordinates access to specialist haematology centres in China and internationally.